Tags

Type your tag names separated by a space and hit enter

Expression of p27kip1 in prostatic adenocarcinoma.
Mod Pathol. 1998 Apr; 11(4):324-8.MP

Abstract

p27kip1 (p27) protein is an inhibitor of cyclin and cyclin-dependent kinase complexes and prevents progression of cells from G1 to the S phase of the cell cycle. p27 might have tumor suppressor activity, and decreased p27 expression is associated with aggressive tumor behavior in several human malignancies. The object of this study was to evaluate p27 expression in prostatic adenocarcinoma treated by radical prostatectomy and to assess its association with numerous morphologic and clinical features. One hundred thirty-eight prostatic adenocarcinomas were evaluated for p27 expression by quantifying nuclear immunohistochemical staining. p27 expression was tested for association with patient age, family history of prostate cancer, preoperative serum prostate-specific antigen level, Gleason score, extraprostatic extension, seminal vesicle involvement, lymph node metastases, tumor-node-metastasis stage, DNA ploidy by flow cytometric analysis, and subclinical biochemical failure. p27 expression was analyzed as a continuous variable, and we also classified the tumors as low expressors (< 50% of cells p27 positive) or high expressors (> 50% of cells p27 positive) for comparison. Patients with adenocarcinomas that exhibited low p27 expression had higher mean Gleason scores than did high expressors (7 vs. 6.2, respectively; P = .002). Low p27 expression correlated with positive surgical margins (P = .05), seminal vesicle involvement (P = .007), lymph node metastasis (P = .03), and aneuploid cancers (P = .003), but it did not correlate with subclinical biochemical failure. p27 expression correlated with a number of prognostic morphologic features in prostatic adenocarcinoma, and the evaluation of p27 expression might provide additional prognostic information.

Authors+Show Affiliations

Cheville JC
Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Lloyd RV
No affiliation info available
Sebo TJ
No affiliation info available
Cheng L
No affiliation info available
Erickson L
No affiliation info available
Bostwick DG
No affiliation info available
Lohse CM
No affiliation info available
Wollan P
No affiliation info available

MeSH

AdenocarcinomaAneuploidyCell Cycle ProteinsCell NucleusCyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesEnzyme InhibitorsFamily HealthGene ExpressionGenes, Tumor SuppressorHumansImmunohistochemistryLymph NodesLymphatic MetastasisMaleMicrotubule-Associated ProteinsMiddle AgedNeoplasm StagingPloidiesProstate-Specific AntigenProstatic NeoplasmsSeminal VesiclesTime FactorsTumor Suppressor Proteins

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9578081

Citation

Cheville, J C., et al. "Expression of P27kip1 in Prostatic Adenocarcinoma." Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, vol. 11, no. 4, 1998, pp. 324-8.
Cheville JC, Lloyd RV, Sebo TJ, et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol. 1998;11(4):324-8.
Cheville, J. C., Lloyd, R. V., Sebo, T. J., Cheng, L., Erickson, L., Bostwick, D. G., Lohse, C. M., & Wollan, P. (1998). Expression of p27kip1 in prostatic adenocarcinoma. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 11(4), 324-8.
Cheville JC, et al. Expression of P27kip1 in Prostatic Adenocarcinoma. Mod Pathol. 1998;11(4):324-8. PubMed PMID: 9578081.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of p27kip1 in prostatic adenocarcinoma. AU - Cheville,J C, AU - Lloyd,R V, AU - Sebo,T J, AU - Cheng,L, AU - Erickson,L, AU - Bostwick,D G, AU - Lohse,C M, AU - Wollan,P, PY - 1998/5/13/pubmed PY - 1998/5/13/medline PY - 1998/5/13/entrez SP - 324 EP - 8 JF - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JO - Mod Pathol VL - 11 IS - 4 N2 - p27kip1 (p27) protein is an inhibitor of cyclin and cyclin-dependent kinase complexes and prevents progression of cells from G1 to the S phase of the cell cycle. p27 might have tumor suppressor activity, and decreased p27 expression is associated with aggressive tumor behavior in several human malignancies. The object of this study was to evaluate p27 expression in prostatic adenocarcinoma treated by radical prostatectomy and to assess its association with numerous morphologic and clinical features. One hundred thirty-eight prostatic adenocarcinomas were evaluated for p27 expression by quantifying nuclear immunohistochemical staining. p27 expression was tested for association with patient age, family history of prostate cancer, preoperative serum prostate-specific antigen level, Gleason score, extraprostatic extension, seminal vesicle involvement, lymph node metastases, tumor-node-metastasis stage, DNA ploidy by flow cytometric analysis, and subclinical biochemical failure. p27 expression was analyzed as a continuous variable, and we also classified the tumors as low expressors (< 50% of cells p27 positive) or high expressors (> 50% of cells p27 positive) for comparison. Patients with adenocarcinomas that exhibited low p27 expression had higher mean Gleason scores than did high expressors (7 vs. 6.2, respectively; P = .002). Low p27 expression correlated with positive surgical margins (P = .05), seminal vesicle involvement (P = .007), lymph node metastasis (P = .03), and aneuploid cancers (P = .003), but it did not correlate with subclinical biochemical failure. p27 expression correlated with a number of prognostic morphologic features in prostatic adenocarcinoma, and the evaluation of p27 expression might provide additional prognostic information. SN - 0893-3952 UR - https://www.unboundmedicine.com/medline/citation/9578081/Expression_of_p27kip1_in_prostatic_adenocarcinoma_ L2 - https://medlineplus.gov/prostatecancer.html DB - PRIME DP - Unbound Medicine ER -